Outcomes After Treatment Re-Initiation in Biochemical Recurrence Prostate Cancer

In this segment, Dr. Graham and Dr. Sokolova explore the clinical implications of treatment re-initiation following a planned suspension in patients with biochemical recurrence prostate cancer. Building on earlier discussion of treatment interruption, the conversation focuses on what available data suggest about disease control once therapy is restarted and how these findings inform long-term patient management. Dr. Sokolova discusses the importance of understanding PSA kinetics, durability of response after re-initiation, and the feasibility of subsequent treatment suspensions in select patients. Both experts emphasize the role of close monitoring and clear communication when counseling patients about expectations over time. The discussion highlights that re-initiation outcomes must be interpreted within the context of trial design and patient selection, rather than generalized to all patients. Overall, this segment reinforces how emerging evidence is shaping more nuanced, individualized counseling strategies for patients with biochemical recurrence prostate cancer undergoing structured treatment interruption approaches.